Literature DB >> 6428864

Plasma GH response to hpGRF-44 in normal children of short stature and patients with GH deficiency.

K Takano, N Hizuka, K Shizume, N C Ling.   

Abstract

Synthetic human pancreatic GRF (hpGRF-44) was administered as an iv bolus to 139 normal children of short stature and 63 patients with GH deficiency. After a dose of 1 and 2 micrograms hpGRF-44/kg BW, mean plasma GH levels peaked at 15 and 30 min, respectively, with corresponding values of 32.2 +/- 3.6 and 31.8 +/- 2.4 (+/- SE) ng/ml in normal but short children. There were no differences according to sex or age in plasma GH response to hpGRF-44 between the ages of 4 and 18 years. A similar plasma GH response was observed when 2 micrograms hpGRF-44/kg BW was administered two hours after lunch. The overall plasma GH response was greater than that of insulin-induced hypoglycemia and was similar to that obtained in the glucagon-propranolol test. Thirty-five of 63 patients with GH deficiency did not respond to a 2 micrograms hpGRF-44/kg BW. However, plasma GH increases to greater than 5 ng/ml occurred in the remaining 28 patients. Their mean GH level reached a peak at 90 min with a value of 8.8 +/- 0.8 ng/ml. These results suggest that hpGRF-44 is useful for evaluating pituitary GH reserve in children of short stature and that some patients with GH deficiency, diagnosed on the basis of established tests, have GH responses to hpGRF-44.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428864     DOI: 10.1507/endocrj1954.31.41

Source DB:  PubMed          Journal:  Endocrinol Jpn        ISSN: 0013-7219


  2 in total

Review 1.  Growth hormone therapy in Canada: end of one era and beginning of another.

Authors:  H J Dean; H G Friesen
Journal:  CMAJ       Date:  1986-08-15       Impact factor: 8.262

2.  Growth hormone releasing factors.

Authors:  R R Davies; D G Johnston
Journal:  J R Soc Med       Date:  1987-01       Impact factor: 18.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.